Kodiak Sciences Inc. , today reported business highlights and financial results for the quarter ended September 30, 2024. "In the third quarter we hosted an Investor R&D Day in New York," said Victor ...

During the loading segment, subjects who have 20/80 vision or better and who satisfy other enrollment criteria receive two ...

EyePoint Pharmaceuticals' lead product, EYP-1901, shows promising phase 2 results for wet AMD and DME. Read more about EYPT ...

Presented positive interim data for 4D-150 in wet age-related macular degeneration (wet AMD) from PRISM Phase 1/2 clinical trial highlighting ...

Each patient in the trial was randomly assigned to receive either a 1.3 mg or 2.7 mg dose of vorolanib via the insert, or aflibercept injections. The company reports that the trial shows a BCVA ...

Part 1 of this 3-part series for Global Biosimilars Week focuses on legal barriers to biosimilar access in the US, including the patent system, and discusses ongoing legislative efforts to address ...

Patients being treated for neovascular age-related macular degeneration (nAMD) appear to have less likelihood of submacular hemorrhage (SMH) when their most recent biologic agent was faricimab, ...

Kalaris is a clinical-stage biopharmaceutical company founded by Samsara BioCapital, dedicated to the development and ...

The global diabetic macular edema market is on a steady growth trajectory, with an expected valuation of approximately USD 4,120.9 million in 2024. The market is poised to surpass USD 4,642.9 million ...

An intravitreal implant (OTX-TKI) containing the tyrosine kinase inhibitor axitinib (Inlyta) was well tolerated and significantly reduced injection frequency by nearly 90% in patients with wet ...

High-dose aflibercept, administered every 12 to 16 weeks for 96 weeks, improves visual acuity in several patient subgroups.

In an interview with David Hutton of Ophthalmology Times, Ash Abbey, MD, discusses the Phase 3 LUGANO trial for EYP-1901 in treating wet age-related macular degeneration. Abbey discusses the trial’s ...